Screening for hydroxychloroquine maculopathy
- Advances in Ophthalmology & Visual System
-
Emad Selim,1 Soad Elsawy,2 Sanjeev Verma,1 Noha Mouselhy,3 Rehab Auf4
Abstract
Introduction: Hydroxychloroquine (HCQ) is an immunosuppressant widely used by rheumatologists in treatment of Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) and other conditions.
Methods: Literature review on reasons why HCQ is commonly prescribed, its side effects and when it is practical to screen for them and what happen if those side effects develop.
Conclusion: Hydroxychloroquine is a disease modified medicine used in rheumatologic diseases. Since retinal toxicity is normally irreversible and progressive even after cessation of medicine, it essential to screen for early feature of retinal toxicity.
Keywords
chloroquine, hydroxychloroquine, maculopathy, rheumatoid arthritis, systemic lupus erythematosus, DMARMs
